MACK - Merrimack Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
12.53
-0.22 (-1.73%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close12.75
Open12.73
Bid12.25 x 100
Ask14.00 x 1500
Day's Range12.36 - 12.79
52 Week Range11.30 - 67.90
Volume183,510
Avg. Volume616,824
Market Cap167.06M
Beta2.22
PE Ratio (TTM)3.90
EPS (TTM)3.21
Earnings DateNov 7, 2017 - Nov 13, 2017
Forward Dividend & Yield0.00 (0.00%)
Ex-Dividend Date2017-05-30
1y Target Est15.00
Trade prices are not sourced from all markets
  • PR Newswire11 days ago

    Merrimack Commences Tender Offer for Any and All of its Outstanding 4.50% Convertible Senior Notes Due 2020

    ISIN No. US590328AA86) (the "Notes"), which amount reflects the consummation of the purchase of the Notes from the Settlement Noteholders (as defined herein) pursuant to the Settlement Agreement (as defined herein). The Company agreed to conduct the Tender Offer in connection with the settlement agreement (the "Settlement Agreement") that it entered into on October 6, 2017 with Wolverine Flagship Fund Trading Limited, 1992 MSF International Ltd. and 1992 Tactical Credit Master Fund, L.P. (collectively, the "Settlement Noteholders") and Wells Fargo Bank, National Association (the "Trustee") to resolve the lawsuit pending in the Court of Chancery in the State of Delaware captioned Wells Fargo Bank, N.A., et al. v. Merrimack Pharmaceuticals, Inc., C.A. No. 2017-0199-JTL filed by the Settlement Noteholders and the Trustee.

  • Merrimack Pharmaceuticals Inc (MACK): How Does It Impact Your Portfolio?
    Simply Wall St.13 days ago

    Merrimack Pharmaceuticals Inc (MACK): How Does It Impact Your Portfolio?

    If you are a shareholder in Merrimack Pharmaceuticals Inc’s (NASDAQ:MACK), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...

  • PR Newswire14 days ago

    Merrimack Announces Settlement of Convertible Note Litigation

    CAMBRIDGE, Mass., Oct. 10, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals (MACK) today announced that it has reached a settlement agreement with Wolverine Flagship Fund Trading Limited, 1992 MSF International Ltd. and 1992 Tactical Credit Master Fund, L.P. (collectively, "Noteholder Plaintiffs") and Wells Fargo Bank, National Association, to resolve the previously disclosed lawsuit captioned Wells Fargo Bank, N.A., et. al. v. Merrimack Pharmaceuticals, Inc. pending in the Court of Chancery in the State of Delaware (the "Delaware Action").

  • Is It Time To Buy Merrimack Pharmaceuticals Inc (MACK)?
    Simply Wall St.last month

    Is It Time To Buy Merrimack Pharmaceuticals Inc (MACK)?

    Merrimack Pharmaceuticals Inc (NASDAQ:MACK), a pharmaceuticals, biotechnology and life sciences company based in United States, saw a significant share price rise of over 20% in the past couple of monthsRead More...

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: American Superconductor and Merrimack Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / September 7, 2017 / After posting the worst daily drop in weeks on rising geopolitical tensions between North Korea and the from their worst daily drop in weeks, U.S. markets ...

  • TheStreet.com2 months ago

    Otonomy Shares Rebound After Wednesday's Drop- Biotech Movers

    Otonomy shares rose in premarket trading on Aug. 31 after plunging Wednesday on the heels of disappointing data in a Phase 3 study of Otividex in patients with Meniere's disease.

  • Merrimack Announces Date of One-for-Ten Reverse Stock Split
    PR Newswire2 months ago

    Merrimack Announces Date of One-for-Ten Reverse Stock Split

    CAMBRIDGE, Mass., Aug. 31, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals (MACK) today announced that the previously disclosed one-for-ten reverse stock split of its issued and outstanding common stock will be effective for trading purposes as of the commencement of trading on September 6, 2017. Merrimack's stockholders approved an amendment to the Company's certificate of incorporation to effect the reverse stock split at the Annual Meeting of Stockholders on August 11, 2017.

  • PR Newswire2 months ago

    Merrimack Augments Executive Team with Appointment of Jean Franchi as Chief Financial Officer

    CAMBRIDGE, Mass., Aug. 14, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals (MACK) today announced that it has strengthened its executive management team with the appointment of Jean M. Franchi as Chief Financial Officer, effective August 21, 2017. In this role, Ms. Franchi will plan and oversee Merrimack's financial strategy to support the ongoing development of multiple clinical- and preclinical-stage product candidates for cancer. Over the course of a 30-year career in the biotechnology and life sciences sectors, Ms. Franchi has held senior financial management roles at several leading companies spanning all stages of development, from research to commercial.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of MACK earnings conference call or presentation 9-Aug-17 12:30pm GMT

    Q2 2017 Merrimack Pharmaceuticals Inc Earnings Call

  • Merrimack (MACK) Q2 Loss Wider than Expected, Stock Falls
    Zacks2 months ago

    Merrimack (MACK) Q2 Loss Wider than Expected, Stock Falls

    Merrimack Pharmaceuticals (MACK) reported wider-than-expected loss in the second quarter. With no marketed product after Onivyde sale, the company is now focused on developing its pipeline candidates.

  • Associated Press2 months ago

    Merrimack misses 2Q profit forecasts

    The Cambridge, Massachusetts-based company said it had profit of $3.86 per share. Losses, adjusted to account for discontinued operations, were 22 cents per share. The results did not meet Wall Street ...

  • Merrimack's (MACK) Reports Wider-than-Expected Q2 Loss
    Zacks2 months ago

    Merrimack's (MACK) Reports Wider-than-Expected Q2 Loss

    Merrimack Pharmaceuticals (MACK) announced second-quarter results, reporting a wider than expected loss of 22 cents per share.

  • PR Newswire2 months ago

    Merrimack Reports Second Quarter 2017 Financial Results

    - Announced hiring of industry veterans Dr. Sergio Santillana as Chief Medical Officer and Thomas Needham as Chief Business Officer to bolster executive team - - Phase 2 CARRIE study of MM-141 completed ...

  • ACCESSWIRE2 months ago

    Investor Network: Merrimack Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 9, 2017 / Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) will be discussing their earnings results in their Q2 Earnings Call to be held on Wednesday, August 9, 2017 ...

  • PR Newswire3 months ago

    Merrimack Announces Timing of Second Quarter 2017 Investor Conference Call

    The call will cover an update on Merrimack's recent progress as well as a summary of second quarter 2017 financial results. A listen-only webcast of the call will be available in the Investors section of Merrimack's website, investors.merrimack.com, and a replay of the call will be archived there for six weeks. Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer to ensure that patients and their families live fulfilling lives.

  • Capital Cube3 months ago

    ETFs with exposure to Merrimack Pharmaceuticals, Inc. : August 1, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Merrimack Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to MACK-US. Comparing the performance and risk of Merrimack Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • What's in the Cards for Merrimack (MACK) in Q2 Earnings?
    Zacks3 months ago

    What's in the Cards for Merrimack (MACK) in Q2 Earnings?

    Sales of Merrimack Pharmaceuticals, Inc???s (MACK) only approved product, Onivyde to Ipsen is expected to bring in $450 million this quarter.

  • PR Newswire3 months ago

    Merrimack Appoints Thomas Needham as Chief Business Officer

    CAMBRIDGE, Mass., July 24, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals (MACK) today announced  further expansion of its executive management team with the appointment of Thomas E. Needham, Jr., M.B.A., to the position of Chief Business Officer. In this role, Mr. Needham will help design and implement Merrimack's strategy for its broad pipeline of clinical and preclinical development assets. Mr. Needham comes to Merrimack with 25 years of experience in corporate strategy, finance and executive management for public and private biotechnology companies.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of MACK earnings conference call or presentation 1-Mar-17 1:30pm GMT

    Q4 2016 Merrimack Pharmaceuticals Inc Earnings Call

  • Accesswire4 months ago

    Biotech Industry Showing Signs of a Revival in 2017: Today's Research on Moleculin Biotech and Merrimack Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / June 22, 2017 / The Biotech Industry has continued to outperform the broader markets in 2017. Biotech companies appear to be benefitting from a speedier FDA approval process ...

  • These 3 Biotechs Have Been Crushed; Is It Time to Bargain Shop?
    Motley Fool4 months ago

    These 3 Biotechs Have Been Crushed; Is It Time to Bargain Shop?

    Disappointing trials from XBiotech, Merrimack Pharmaceuticals, and NewLink Genetics have earned the market's ire. But are their declines overdone?

  • Merrimack Completes Enrollment in Phase II Study for MM-141
    Zacks4 months ago

    Merrimack Completes Enrollment in Phase II Study for MM-141

    Merrimack Pharmaceuticals announced completion of enrollment in the ongoing phase II study, evaluatingMM-141 in combination with standard of care for treatment of patients with previously untreated metastatic pancreatic cancer.

  • PR Newswire4 months ago

    Merrimack Announces Completion of Enrollment in Phase 2 CARRIE Study of MM-141; Data Expected in First Half of 2018

    CAMBRIDGE, Mass., June 19, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (MACK) today announced that it has enrolled the last patient in the ongoing CARRIE study, a Phase 2, double-blind, placebo-controlled, randomized trial, evaluating MM-141 (istiratumab) in combination with standard of care in previously untreated patients with metastatic pancreatic cancer.  MM-141 is a bispecific antibody targeting both the Insulin Like Growth Factor 1 Receptor (IGF-1R) and the HER3 receptor, and is a potent inhibitor of the PI3K/AKT/mTOR signaling pathway. "Today, as we recognize the 10th anniversary of the National Pancreatic Cancer Advocacy Day, we are marking a significant milestone with the CARRIE study, which reflects both the significant need for new therapies in metastatic pancreatic cancer and the potential of MM-141 to play a critical role in addressing that need," said Richard Peters, M.D., Ph.D., President and Chief Executive Officer of Merrimack.

  • Why Is Merrimack (MACK) Down 57.6% Since the Last Earnings Report?
    Zacks4 months ago

    Why Is Merrimack (MACK) Down 57.6% Since the Last Earnings Report?

    Merrimack (MACK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Merrimack Announces Expansion of Senior Management Team with Appointment of Sergio Santillana as Chief Medical Officer and Ellen Forest as Head of Human Resources
    PR Newswire5 months ago

    Merrimack Announces Expansion of Senior Management Team with Appointment of Sergio Santillana as Chief Medical Officer and Ellen Forest as Head of Human Resources

    CAMBRIDGE, Mass., June 8, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced the expansion of its senior management team through the addition of two new executive hires. ...